Population | Rheumatoid arthritis |
Intervention | Analysis of costs in RA (treatment and societal costs) |
Control |
|
Outcome |
|
ABA, abatacept; ADA, adalimumab; DMARD, disease-modifying antirheumatic drug; ETA, etanercept; HCQ, hydroxychloroquine; IFX, infliximab; LEF, leflunomide; MTX, methotrexate; RTX, rituximab; SSZ, sulfasalazine; TCZ, tocilizumab.